Iressa Lung Cancer Drug Eyed As Worthy Candidate For Companion Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Early collaborations between drug and diagnostic firms frequently yield favorable FDA review of pharmaceutical data, speakers attested at SMI's Opportunities & Technology Trends in Global Diagnostic Testing Markets conference in London June 28-29